Daclizumab是一种人源化单克隆抗体，通过靶向阻断CD25（高亲和力白细胞介素-2 受体 α 亚基，IL-2Rα）发挥作用。其作用机制包括：抑制效应T细胞的活化、限制调节性T细胞（Treg）的增殖与存活，并调节激活诱导的 T 细胞凋亡，多发性硬化症及炎症相关疾病的研究。

Purity:SDS-PAGE

Anti-IL-2Ra / CD25 Reference Antibody (daclizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC

The purity of Anti-IL-2Ra / CD25 Reference Antibody (daclizumab) is 99.49%, determined by SEC-HPLC.

Bioactivity:ELISA

Immobilized human IL 2R His at 2 ug/mL can bind Anti-IL-2Ra / CD25 Reference Antibody (daclizumab), EC50=0.002707 ug/mL.

-25~-15℃保存，有效期1年。